TY - JOUR
T1 - The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012
T2 - Practice parameters with an evidence-based systematic review and meta-analyses
AU - Aurora, R. Nisha
AU - Kristo, David A.
AU - Bista, Sabin R.
AU - Rowley, James A.
AU - Zak, Rochelle S.
AU - Casey, Kenneth R.
AU - Lamm, Carin I.
AU - Tracy, Sharon L.
AU - Rosenberg, Richard S.
PY - 2012/8/1
Y1 - 2012/8/1
N2 - A systematic literature review and meta-analyses (where appropriate) were performed to update the previous AASM practice parameters on the treatments, both dopaminergic and other, of RLS and PLMD. A considerable amount of literature has been published since these previous reviews were performed, necessitating an update of the corresponding practice parameters. Therapies with a ST ANDARD level of recommendation include pramipexole and ropinirole. Therapies with a GUIDELINE level of recommendation include levodopa with dopa decarboxylase inhibitor, opioids, gabapentin enacarbil, and cabergoline (which has additional caveats for use). Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation. The committee recommends a ST ANDARD AGAINST the use of pergolide because of the risks of heart valve damage. Therapies for RLS secondary to ESRD, neuropathy, and superficial venous insufficiency are discussed. Lastly, therapies for PLMD are reviewed. However, it should be mentioned that because PLMD therapy typically mimics RLS therapy, the primary focus of this review is therapy for idiopathic RLS.
AB - A systematic literature review and meta-analyses (where appropriate) were performed to update the previous AASM practice parameters on the treatments, both dopaminergic and other, of RLS and PLMD. A considerable amount of literature has been published since these previous reviews were performed, necessitating an update of the corresponding practice parameters. Therapies with a ST ANDARD level of recommendation include pramipexole and ropinirole. Therapies with a GUIDELINE level of recommendation include levodopa with dopa decarboxylase inhibitor, opioids, gabapentin enacarbil, and cabergoline (which has additional caveats for use). Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation. The committee recommends a ST ANDARD AGAINST the use of pergolide because of the risks of heart valve damage. Therapies for RLS secondary to ESRD, neuropathy, and superficial venous insufficiency are discussed. Lastly, therapies for PLMD are reviewed. However, it should be mentioned that because PLMD therapy typically mimics RLS therapy, the primary focus of this review is therapy for idiopathic RLS.
KW - PLMD
KW - Periodic limb movement disorder
KW - RLS
KW - Restless legs syndrome
KW - Sleep-related movement disorders
UR - http://www.scopus.com/inward/record.url?scp=84864762471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864762471&partnerID=8YFLogxK
U2 - 10.5665/sleep.1988
DO - 10.5665/sleep.1988
M3 - Review article
C2 - 22851801
AN - SCOPUS:84864762471
SN - 0161-8105
VL - 35
SP - 1039
EP - 1062
JO - Sleep
JF - Sleep
IS - 8
ER -